Trial Profile

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emactuzumab (Primary)
Indications Giant cell tumour of tendon sheath
Focus Registrational; Therapeutic Use
Acronyms TANGENT
Sponsors SynOx Therapeutics

Most Recent Events

29 Jul 2026 Planned End Date changed from 30 Sep 2027 to 30 Sep 2030.
18 May 2026 Planned number of patients changed from 144 to 145.
11 May 2026 Planned number of patients changed from 137 to 144.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com